Evidence map›Paper›PMID 35093310›Full record

ReviewEnvironmental research2022

Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic.

Rekha Khandia, Shailja Singhal, Taha Alqahtani, Mohammad Amjad Kamal, Nahed A El-Shall, Firzan Nainu, Perumal Arumugam Desingu, Kuldeep Dhama

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Environmental research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 159 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
159citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

159 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

99 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rekha KhandiaDepartment of Biochemistry and Genetics, Barkatullah University, Bhopal, 462026, MP, India. Electronic address: bu.rekha.khandia@gmail.com.
Shailja SinghalDepartment of Biochemistry and Genetics, Barkatullah University, Bhopal, 462026, MP, India.
Taha AlqahtaniDepartment of Pharmacology, College of Pharmacy, King Khalid University, 62529, Abha, Saudi Arabia.
Mohammad Amjad KamalInstitutes for Systems Genetics, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China; King Fahd Medical Research Center, King Abdulaziz University, Saudi Arabia; Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, Bangladesh; Enzymoics, 7 Peterlee place, Hebersham, NSW, 2770, Novel Global Community Educational Foundation, Australia.
Nahed A El-ShallDepartment of Poultry and Fish Diseases, Faculty of Veterinary Medicine, Alexandria University, Edfina, El-Beheira, 22758, Egypt.
Firzan NainuDepartment of Pharmacy, Faculty of Pharmacy, Hasanuddin University, Makassar, 90245, Indonesia.
Perumal Arumugam DesinguDepartment of Microbiology and Cell Biology, Indian Institute of Science, Bengaluru, 560012, India.
Kuldeep DhamaDivision of Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, 243122, Uttar Pradesh, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the appearance in the late of December 2019, SARS-CoV-2 is rapidly evolving and mutating continuously, giving rise to various variants with variable degrees of infectivity and lethality. The virus that initially appeared in China later mutated several times, wreaking havoc and claiming many lives worldwide amid the ongoing COVID-19 pandemic. After Alpha, Beta, Gamma, and Delta variants, the most recently emerged variant of concern (VOC) is the Omicron (B.1.1.529) that has evolved due to the accumulation of high numbers of mutations especially in the spike protein, raising concerns for its ability to evade from pre-existing immunity acquired through vaccination or natural infection as well as overpowering antibodies-based therapies. Several theories are on the surface to explain how the Omicron has gathered such a high number of mutations within less time. Few of them are higher mutation rates within a subgroup of population and then its introduction to a larger population, long term persistence and evolution of the virus in immune-compromised patients, and epizootic infection in animals from humans, where under different immune pressures the virus mutated and then got reintroduced to humans. Multifaceted approach including rapid diagnosis, genome analysis of emerging variants, ramping up of vaccination drives and receiving booster doses, efficacy testing of vaccines and immunotherapies against newly emerged variants, updating the available vaccines, designing of multivalent vaccines able to generate hybrid immunity, up-gradation of medical facilities and strict implementation of adequate prevention and control measures need to be given high priority to handle the on-going SARS-CoV-2 pandemic successfully.

Indexed as

COVID-19AnimalsGlobal HealthHumansPandemicsSARS-CoV-2Immune escapeOmicronOmicron originPrevention and controlVaccine failureVariant of concern

Identifiers

PMID35093310
PMCPMC8798788

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.